TNSN00094A1 - NEW COMPOSITION - Google Patents

NEW COMPOSITION

Info

Publication number
TNSN00094A1
TNSN00094A1 TNTNSN00094A TNSN00094A TNSN00094A1 TN SN00094 A1 TNSN00094 A1 TN SN00094A1 TN TNSN00094 A TNTNSN00094 A TN TNSN00094A TN SN00094 A TNSN00094 A TN SN00094A TN SN00094 A1 TNSN00094 A1 TN SN00094A1
Authority
TN
Tunisia
Prior art keywords
new composition
methylthiazole
stabilities
chloroethyl
physiological
Prior art date
Application number
TNTNSN00094A
Other languages
French (fr)
Inventor
Ellstrom Karin
Petersson-Norden Tomas
Jappinen Ingrid
Camber Ola
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TNSN00094A1 publication Critical patent/TNSN00094A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENTION SE RAPPORTE A UNE COMPOSITION PARENTERALE DE 5-(2-CHLOROETHYL)- 4-METHYLTHIAZOLE (GENERIQUEMENT DESIGNE EDISYLATE DE CLOMETHIAZOLE) POSSEDANT DES PROPRIETES ANTIMICROBIENNES AMELIOREES EN PLUS DE LA STABILITE PHYSIQUE, CHIMIQUE ET MICROBIOLOGIQUE ET DE LA COMPATIBILITE BIOLOGIQUE.THE PRESENT INVENTION RELATES TO A PARENTERAL COMPOSITION OF 5- (2-CHLOROETHYL) - 4-METHYLTHIAZOLE (GENERICALLY DESIGNED CLOMETHIAZOLE EDISYLATE) HAVING IMPROVED ANTIMICROBIAL AND BIOLOGICAL AND PHYSIOLOGICAL STABILITIES.

TNTNSN00094A 1999-05-06 2000-05-03 NEW COMPOSITION TNSN00094A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901658A SE9901658D0 (en) 1999-05-06 1999-05-06 New formulation

Publications (1)

Publication Number Publication Date
TNSN00094A1 true TNSN00094A1 (en) 2002-05-30

Family

ID=20415507

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00094A TNSN00094A1 (en) 1999-05-06 2000-05-03 NEW COMPOSITION

Country Status (7)

Country Link
EP (1) EP1178798A1 (en)
JP (1) JP2002544164A (en)
AR (1) AR023873A1 (en)
AU (1) AU4792200A (en)
SE (1) SE9901658D0 (en)
TN (1) TNSN00094A1 (en)
WO (1) WO2000067753A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK733888A (en) * 1988-01-12 1989-07-13 Fujisawa Pharmaceutical Co stabilizer
IL91856A0 (en) * 1988-10-11 1990-06-10 Schiapparelli Salute Spa Pharmaceutical compositions comprising calcitonin for intranasal administration and a spray unit for the administration of the same
SE8900564D0 (en) * 1989-02-17 1989-02-17 Astra Ab NOVEL MEDICINAL USE
SE9002659D0 (en) * 1990-08-15 1990-08-15 Astra Ab NEW PHARMACEUTICAL FORMULATIONS

Also Published As

Publication number Publication date
JP2002544164A (en) 2002-12-24
SE9901658D0 (en) 1999-05-06
AR023873A1 (en) 2002-09-04
EP1178798A1 (en) 2002-02-13
WO2000067753A1 (en) 2000-11-16
AU4792200A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
NO20035327D0 (en) Biologically active methylene-blue derivatives
MA30162B1 (en) NEW FUSED CYCLE PYRROLE DERIVATIVES
TNSN02011A1 (en) NOVEL BICYCLIC PYRIMIDINE DERIVATIVES, MMP INHIBITORS, AND COMPOSITIONS CONTAINING THEM
TR200000059T2 (en) Pyridine derivatives
TNSN01012A1 (en) AMINO DERIVATIVES OF DIHYDRO-1, 3,5-TRIAZINE AND THEIR THERAPEUTIC APPLICATIONS
JO2475B1 (en) Glucokinase Activators
TR200402577T4 (en) Uracil compounds and their use
ATE242267T1 (en) EXTENDIN-4 CONJUGATES AND THEIR MEDICAL USES
TNSN01048A1 (en) MALONAMIC ACIDS AND DERIVATIVES THEREOF, AND COMPOSITIONS CONTAINING THEM
FI882390A0 (en) Tetrazoles, which are intermediates in antihypertensive compounds
TR200101744T2 (en) Phenylglycine derivatives.
ATE270817T1 (en) FUNGICIDES
WO2001066564A3 (en) Gamma-secretase inhibitors
ATE260255T1 (en) 5-OXO-PYRROLIDINE-2-CARBONIC ACID HYDROXAMIDE DERIVATIVES
NZ330973A (en) Azolobenzazepine derivatives as neurologically active agents
TR200200449T2 (en) Active ingredient combination containing clonidine
CA2327635A1 (en) Uracil compounds and use thereof
ATE244245T1 (en) CONDENSED THIOPHENE DERIVATIVES AND THEIR MEDICAL APPLICATIONS
TR199800543A2 (en) Benzyloxy substituted anilylated N-heterocyclic compounds.
DE69610628D1 (en) N- (2,4-DIOXO-2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPIN-3-YL) -3-AMIDE
DE60234424D1 (en) Biguanidderivate
TNSN00094A1 (en) NEW COMPOSITION
BR0115139A (en) Bisheterocyclic compounds with antitumor and chemosensitizing activity
PT1056754E (en) DIARILO 1,3,4-OXADIAZOLONE PHOSPHATE DERIVATIVES
TR199800301A2 (en) S�lfonamid-substit�e edilmi� 7 halkal� bile�ikler.